SELECTIVE CDK4/6 INHIBITOR CANCER THERAPEUTICS

This disclosure describes embodiments of selective and potent CDK 4/6 inhibitors that show advantageous inhibition of cancer growth, even at low concentrations. As described herein, compounds of the present approach comprise substituted pyridinylpiperazine-pyrrolopyrimidine compounds having a fatty...

Full description

Saved in:
Bibliographic Details
Main Authors FEDERICA SOTGIA, MICHAEL P LISANTI, JUSSI KANGASMETSA
Format Patent
LanguageEnglish
Published 30.05.2024
Online AccessGet full text

Cover

More Information
Summary:This disclosure describes embodiments of selective and potent CDK 4/6 inhibitors that show advantageous inhibition of cancer growth, even at low concentrations. As described herein, compounds of the present approach comprise substituted pyridinylpiperazine-pyrrolopyrimidine compounds having a fatty acid moiety. The compounds described herein may be used as pharmaceutical compounds for anti-cancer therapies, and are useful for the treatment, prevention and/or amelioration of cancer. Formula (a).
Bibliography:Application Number: ZA20220013053